


ADC

CMC

GLP

2023

32



Overview of the natural function of antibodies^[1]



VHH

VHH

ELISA

B

B

B


Ig

, ,


B




B




Nectin-4 Mouse Serum Titer







Nectin-4 (4-1) Sorting Single B Cell




Nectin-4 (4-6) Sorting Single B Cell




Raji cells were mixed with human PBMCs, and different doses of Rituximab was added to induce ADCC, the killing of raji cells were detected through FACS(CFSE labeling of raji).



Raji cells were mixed with human AB serum, and different doses of Rituximab was added to induce CDC, the killing of raji cells were detected through FACS(PI staining of raji).




B cells were treated with Teliacept and induced with Baff for 72 hours, H3-thymidine incorporation were analyzed through scintillation counting.



T cells were treated with compound A and induced with ICOSL for 72 hours, H3-thymidine incorporation were analyzed through scintillation counting.



- A/IgG1 CD3/LPS PBMC 25
Luminex TNFα
- ICH IL-2
IL-6 IL-10 IFN-γ TNF-α PBMC
3 ELISA Luminex CBA
MSD OKT3
-



2022 2

LQ036
LQ036

IL-4R α

() IND

CDE


LQ036

LQ036

NMPA

TGA

8 CD3+ Bispecific Antibody



- ? Ig k_jq8
Female NOG mice
- Rs k mp Acjjq8
Tumor mixed hPBMC (1:1) with 50% Matrigel, SC
- N@KA8
injected before tumor cells inoculation
- Rpc_r k c l r8
Bispecific antibody

Mean Tumor Volum (mm³) Day 14

Group	TV	%TGI _{TV}	P Value

/

PK

: Pharmacokinetics of YYB-101 in cynomolgus monkeys

YYB-101

10 mg/kg

T_{max}

Pharmacokinetic profile of YYB-101 in cynomolgus monkeys^[4]

YYB-101	50mg/kg	29	85
1			
	I		
			(NCT02499224)

Toxicokinetic parameters on days 1 and 22 following intravenous infusion of YYB-101 at 10, 50, or 200 mg/kg perday in cynomolgus monkeys^[4]

BAT6021

BAT6005

20219

BAT6021

BAT6005

BAT6021

BAT6005

TIGIT

BAT6021

BAT6005

BAT7104

202110

PD-L1/CD47

BAT7104

BAT7104

PD-L1/CD47

PD-1/PD-L1

CD47/SIRP- α

BAT7104

BAT7104

GLP

BAT7104

BAT7104

JYB1904

20225

JYB1904

IgE

JYB1904

JYB1904

IgE

GLP

JYB1904

JYB1904

CC312

20226

CD19/CD3/CD28

CC312

IND

FDA

CD28

CC312

GLP

CC312

GT90008

202210

PD-L1/TGF- β

(GT90008)

GT90008

PD-L1/TGF- β

PD-L1

TGF- β R2

GT90008

GLP

/

HCW9218

2022 10 HCW Biologics Inc. HCW9218 FDA HCW9218
TGF-β II IL-15/IL-15 α NK CD8+ T
HCW HCW GLP
HCW9218
SEND HCW9218 FDA

:

[1] Ivana Spasevska. An outlook on bispecific antibodies: Methods of production and therapeutic benefits.

[2] Abdullah F U H Saeed, et al. Antibody Engineering for Pursuing a Healthier Future. Front Microbiol. 2017 Mar 28;8:495. doi: 10.3389/fmicb.2017.00495.